10,135 Shares in Charles River Laboratories International, Inc. $CRL Purchased by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. bought a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the second quarter, according to the company in its most recent filing with the SEC. The firm bought 10,135 shares of the medical research company’s stock, valued at approximately $1,538,000.

Other hedge funds have also made changes to their positions in the company. Brooklyn Investment Group increased its position in shares of Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after purchasing an additional 86 shares in the last quarter. HM Payson & Co. acquired a new stake in shares of Charles River Laboratories International during the 1st quarter worth about $31,000. Family Legacy Financial Solutions LLC acquired a new stake in shares of Charles River Laboratories International during the 2nd quarter worth about $71,000. Parallel Advisors LLC increased its position in shares of Charles River Laboratories International by 83.7% during the 1st quarter. Parallel Advisors LLC now owns 474 shares of the medical research company’s stock worth $71,000 after purchasing an additional 216 shares in the last quarter. Finally, ORG Wealth Partners LLC grew its holdings in Charles River Laboratories International by 49.8% during the 2nd quarter. ORG Wealth Partners LLC now owns 496 shares of the medical research company’s stock worth $77,000 after acquiring an additional 165 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Joseph W. Laplume sold 800 shares of Charles River Laboratories International stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $157.60, for a total transaction of $126,080.00. Following the transaction, the executive vice president owned 24,116 shares of the company’s stock, valued at $3,800,681.60. This trade represents a 3.21% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.30% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. JPMorgan Chase & Co. increased their price objective on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Jefferies Financial Group raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and increased their price objective for the stock from $142.00 to $195.00 in a report on Tuesday, September 9th. Evercore ISI increased their price objective on shares of Charles River Laboratories International from $180.00 to $190.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. Wall Street Zen raised shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a report on Monday. Finally, Citigroup raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $150.00 to $200.00 in a report on Wednesday, July 9th. Six analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $177.07.

Charles River Laboratories International Stock Up 8.9%

Shares of NYSE CRL opened at $170.42 on Thursday. The firm has a market capitalization of $8.39 billion, a PE ratio of -128.13, a price-to-earnings-growth ratio of 4.18 and a beta of 1.50. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $230.02. The firm’s 50-day moving average is $159.51 and its 200-day moving average is $147.47.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.62. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $983.76 million. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The company’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter last year, the firm earned $2.80 EPS. Equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).